365 related articles for article (PubMed ID: 18498916)
41. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
Tönshoff B; David-Neto E; Ettenger R; Filler G; van Gelder T; Goebel J; Kuypers DR; Tsai E; Vinks AA; Weber LT; Zimmerhackl LB
Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
[TBL] [Abstract][Full Text] [Related]
42. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
43. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy.
Weber LT; Shipkova M; Armstrong VW; Wagner N; Schütz E; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B
J Am Soc Nephrol; 2002 Mar; 13(3):759-768. PubMed ID: 11856782
[TBL] [Abstract][Full Text] [Related]
44. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
45. Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant.
Ciftci HS; Demir E; Karadeniz MS; Tefik T; Nane I; Oguz FS; Aydin F; Turkmen A
Ren Fail; 2018 Nov; 40(1):395-402. PubMed ID: 30012031
[TBL] [Abstract][Full Text] [Related]
46. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.
Kuypers DR; Ekberg H; Grinyó J; Nashan B; Vincenti F; Snell P; Mamelok RD; Bouw RM
Clin Pharmacokinet; 2009; 48(5):329-41. PubMed ID: 19566116
[TBL] [Abstract][Full Text] [Related]
47. Short-term therapeutic drug monitoring of mycophenolic acid reduces infection: a prospective, single-center cohort study in Chinese living-related kidney transplantation.
Fu L; Huang Z; Song T; He S; Zeng D; Rao Z; Xie L; Song Y; Wang L; Lin T
Transpl Infect Dis; 2014 Oct; 16(5):760-6. PubMed ID: 25092411
[TBL] [Abstract][Full Text] [Related]
48. Association of UDP-glucuronosyltransferase 1A9 (UGT1A9) gene polymorphism with kidney allograft function.
Pazik J; Ołdak M; Dąbrowski M; Lewandowski Z; Sitarek E; Podgórska M; Ważna E; Płoski R; Szmidt J; Chmura A; Durlik M; Malejczyk J
Ann Transplant; 2011; 16(4):69-73. PubMed ID: 22210424
[TBL] [Abstract][Full Text] [Related]
49. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.
Brunet M; Martorell J; Oppenheimer F; Vilardell J; Millán O; Carrillo M; Rojo I; Corbella J
Transpl Int; 2000; 13 Suppl 1():S301-5. PubMed ID: 11112019
[TBL] [Abstract][Full Text] [Related]
51. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.
Kuypers DR; Vanrenterghem Y; Squifflet JP; Mourad M; Abramowicz D; Oellerich M; Armstrong V; Shipkova M; Daems J
Ther Drug Monit; 2003 Oct; 25(5):609-22. PubMed ID: 14508385
[TBL] [Abstract][Full Text] [Related]
52. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
Zhu L; Ding T; Wang XX; Lin ZB; Chen G
Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
[TBL] [Abstract][Full Text] [Related]
53. Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients.
Kulabusaya B; Vadcharavivad S; Avihingsanon Y; van Gelder T; Praditpornsilpa K
Int J Clin Pharm; 2019 Aug; 41(4):1047-1055. PubMed ID: 31129889
[TBL] [Abstract][Full Text] [Related]
54. Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients.
Satoh S; Tada H; Murakami M; Tsuchiya N; Li Z; Numakura K; Saito M; Inoue T; Miura M; Hayase Y; Suzuki T; Habuchi T
Transplantation; 2006 Aug; 82(4):486-93. PubMed ID: 16926592
[TBL] [Abstract][Full Text] [Related]
55. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
[TBL] [Abstract][Full Text] [Related]
56. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring?
Cox VC; Ensom MH
Ther Drug Monit; 2003 Apr; 25(2):137-57. PubMed ID: 12657908
[TBL] [Abstract][Full Text] [Related]
57. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
van Gelder T; Silva HT; de Fijter H; Budde K; Kuypers D; Mamelok RD; Armstrong VW; Oellerich M
Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients.
Ensom MH; Partovi N; Decarie D; Dumont RJ; Fradet G; Levy RD
Ther Drug Monit; 2002 Apr; 24(2):310-4. PubMed ID: 11897977
[TBL] [Abstract][Full Text] [Related]
59. Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil.
Cilião HL; Camargo-Godoy RBO; Souza MF; Zanuto A; Delfino VDA; Cólus IMS
Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt B):97-102. PubMed ID: 30442353
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients.
Graff J; Scheuermann EH; Brandhorst G; Oellerich M; Gossmann J
Ther Drug Monit; 2016 Jun; 38(3):388-92. PubMed ID: 26829599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
